Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Recruiting
Phase 3
Interventional Study
Cardiotoxicity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 1 – 18
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 30 (estimated)
- Sponsor
- Ain Shams University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
* Ability to take oral medication.
* Age 2-18 years at the time of diagnosis.
Exclusion Criteria:
* Documented allergy to cardioprotective medications
Contacts